S&CO Inc. Purchases 2,876 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• S&CO Inc. increased its holdings in Intuitive Surgical by 128.1% during the first quarter, bringing its total shares to 5,121, valued at approximately $2.54 million.
• Intuitive Surgical reported EPS of $2.19 for the last quarter, exceeding analyst expectations of $1.93, with a revenue of $2.44 billion.
• Analysts have mixed ratings for Intuitive Surgical, with target prices ranging from $440 to $650, resulting in a consensus rating of "Moderate Buy."

S&CO Inc. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 128.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,121 shares of the medical equipment provider's stock after purchasing an additional 2,876 shares during the quarter. S&CO Inc.'s holdings in Intuitive Surgical were worth $2,536,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ISRG. Chilton Capital Management LLC grew its stake in Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares during the period. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth about $26,000. Global Financial Private Client LLC boosted its position in shares of Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares during the period. Elite Financial Inc. acquired a new position in shares of Intuitive Surgical during the first quarter worth about $26,000. Finally, Hurley Capital LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth about $28,000. Institutional investors own 83.64% of the company's stock.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,500 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president directly owned 353 shares in the company, valued at approximately $173,845.44. This represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president owned 907 shares of the company's stock, valued at approximately $510,740.77. This represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,903 shares of company stock worth $7,932,778. Company insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ISRG. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. UBS Group upped their target price on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Wells Fargo & Company upped their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research note on Wednesday, July 23rd. Piper Sandler restated an "overweight" rating and issued a $595.00 price objective (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Finally, Royal Bank Of Canada upped their price objective on Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a research note on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $592.05.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $2.03 during trading on Friday, hitting $483.12. 2,978,043 shares of the company's stock traded hands, compared to its average volume of 2,000,215. The stock has a fifty day moving average of $525.14 and a two-hundred day moving average of $533.73. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00. The firm has a market cap of $173.19 billion, a P/E ratio of 67.38, a PEG ratio of 5.25 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company's revenue was up 21.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.78 earnings per share. As a group, analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.